Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Multiple Sclerosis
Acorda Therapeutics Reports Third Quarter 2007 Financial Results
November 19th, 2007
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced its financial results for the third quarter 2007. "We are very happy with the rapid enrollment in our second Phase 3 trial of Fampridine-SR, and look forward to reporting results from this trial in the second quarter of 2008, as well as results of our Thorough QT cardiac study in the first quarter," said Ron Cohen, M.D., President and CEO of Acorda Therapeutics. "In addition, we were pleased with the continued growth of our Zanaflex business. Based on our current projections, we expect our Zanaflex commercial operations to be cash flow neutral by the end of calendar 2007 and cash flow positive in 2008. This growth...
Source: Pain & Central Nervous System Week (2007-11-19)
|
